Phase I/II study of tecemotide cancer immunotherapy for Japanese patients with unresectable stage III non-small cell lung cancer (NSCLC).

被引：3

作者：

Nokihara, Hiroshi

Katakami, Nobuyuki

Hida, Toyoaki

Imamura, Fumio

Sakai, Hiroshi

Atagi, Shinji

Nishio, Makoto

Helwig, Christoph

Achiwa, Hiroyuki

Tamura, Tomohide

机构：

[1] Natl Canc Ctr, Tokyo, Japan

[2] Inst Biomed Res & Innovat, Kobe, Hyogo, Japan

[3] Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi 464, Japan

[4] Osaka Med Ctr, Osaka, Japan

[5] Saitama Canc Ctr, Saitama, Japan

[6] Kinki Chuo Chest Med Ctr, Osaka, Japan

[7] Japanese Fdn Canc Res, Tokyo, Japan

[8] Merck KGaA, Darmstadt, Germany

[9] Merck Serono Co Ltd, Tokyo, Japan

[10] St Lukes Int Hosp, Tokyo, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期

关键词：

D O I：

10.1200/jco.2015.33.15_suppl.3036

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3036

引用

页数：1

共 50 条

[11] A phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non squamous, non-small cell lung cancer (NSCLC)
Tredaniel, J.
Mornex, F.
Barillot, I.
Diaz, O.
Hennequin, C.
Le Pechoux, C.
Lavole, A.
Giraud, P.
Souquet, P. -J.
Teixeira, L.
Vaylet, F.
Zalcman, G.
Baudrin, L.
Morin, F.
Milleron, B.
REVUE DES MALADIES RESPIRATOIRES, 2011, 28 (01) : 51 - 57
[12] Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses
Mitchell, P.
Thatcher, N.
Socinski, M. A.
Wasilewska-Tesluk, E.
Horwood, K.
Szczesna, A.
Martin, C.
Ragulin, Y.
Zukin, M.
Helwig, C.
Falk, M.
Butts, C.
Shepherd, F. A.
ANNALS OF ONCOLOGY, 2015, 26 (06) : 1134 - 1142
[13] RADIOTHERAPY FOR STAGE III NON-SMALL CELL LUNG CANCER (NSCLC)
De Ruysscher, D.
LUNG CANCER, 2009, 64 : S21 - S21
[14] Radiation therapy of stage I and II non-small cell lung cancer (NSCLC)
Zierhut, D
Bettscheider, C
Schubert, K
van Kampen, M
Wannenmacher, M
LUNG CANCER, 2001, 34 : S39 - S43
[15] Chemoradiation in older patients with stage III non-small cell lung cancer (NSCLC)
Ng, Dawn M.
Sun, Alex
Coate, Linda
Ma, Clement
Bezjak, Andrea
Brade, Anthony
Burkes, Ronald L.
Cho, John
Feld, Ronald
Liu, Geoff
Shepherd, Frances
Leighl, Natasha B.
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S858 - S858
[16] Immunotherapy for non-small cell lung cancer (NSCLC)
Frost, Nikolaj
Reck, Martin
INNERE MEDIZIN, 2022, 63 (07): : 709 - 716
[17] Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable, Stage III Non-Small Cell Lung Cancer: A Phase I Study
Higgins, K.
Pillai, R.
Chen, Z.
Zhang, C.
Patel, P.
Pakkala, S.
Shelton, J.
Force, S.
Fernandez, F.
Steuer, C.
Owonikoko, T.
Ramalingam, S.
Bradley, J.
Curran, W., Jr.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2013 - S2014
[18] Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer
Sekine, I
Noda, K
Oshita, F
Yamada, K
Tanaka, M
Yamashita, K
Nokihara, H
Yamamoto, N
Kunitoh, H
Ohe, Y
Tamura, T
Kodama, T
Sumi, M
Saijo, N
CANCER SCIENCE, 2004, 95 (08) : 691 - 695
[19] Phase II study of dasatinib in non-small cell lung cancer (NSCLC)
Johnson, F. M.
Tang, X.
Tran, H.
Saigal, B.
Erasmus, J.
Kurie, J.
Hwang, L.
Oh, Y.
Lippman, S.
Stewart, D. J.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[20] TECEMOTIDE (L-BLP25) IN UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER IN THE PHASE III START STUDY: FURTHER ENDPOINT AND EXPLORATORY BIOMARKER RESULTS
Mitchell, Paul L.
Butts, Charles A.
Socinski, Mark A.
Thatcher, Nicholas
Wickart-Johansson, Gun
Ellis, Peter M.
Gladkov, Oleg
Pereira, Jose R.
Eberhardt, Wilfried E. E.
Horwood, Keith
Szczesna, Aleksandra
Helwig, Christoph
Schroeder, Andreas
Shepherd, Frances A.
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S135 - S136

← 1 2 3 4 5 →